Adrenal Fatigue Institute Participates In ERSP Forum

New York, NY – June  24, 2009  – The Electronic Retailing Self-Regulation Program (ERSP) has determined that the Adrenal Fatigue Institute has provided a reasonable basis for several performance claims related to adrenal functioning, metabolism, and fatigue for the Cylapril Dietary Supplement, but recommended discontinuing claims related to weight loss. The marketer’s advertising came to ERSP’s attention pursuant to ERSP’s routine monitoring efforts.

ERSP, the electronic direct-response industry’s self-regulatory forum, is administered by the Council of Better Business Bureaus (CBBB) with policy oversight by the National Advertising Review Council (NARC).

ERSP’s inquiry focused on claims included in online advertising. Claims at issue in the ERSP inquiry included:

  • “The ONLY product of its kind to combat Adrenal Fatigue Burnout, period”
  •  “Increase weight loss, energy & mood faster!”
  • “It’s a unique formulation of ingredients that will revitalize your adrenal system and restore it to optimal effectiveness so you can finally lose weight.”
  •  “Cleanse your adrenal system, shed the weight”
  •   “Cylapril™ has been formulated to offer needed support to the over-taxed adrenal gland and help take the workload off the adrenal system so it can repair itself naturally.”
  • “The Cylapril™ Anti Stress & Energy Revitalizer is the second stage of the Cylapril™ Adrenal Cleansing System. This formula helps to reduce the amount of stress that you experience and it reduces its impact on your Adrenal system. Along with the Bee Pollen, a potent antioxidant, the Anti Stress & Energy Revitalizer provides aid in reducing anxiety, increasing mental performance, and reducing fatigue.

 

During the course of the inquiry, the marketer advised ERSP that it had voluntarily discontinued claims that Cylapril is “The ONLY product of its kind to combat Adrenal Fatigue Burnout…” and, that by using its products, consumers would “Increase weight loss, energy & mood faster!” It also voluntarily discontinued testimonials claiming any specific amount of weight loss.

 

ERSP agreed that the Adrenal Fatigue Institute provided adequate support for the claims that Cylapril enhances adrenal functioning, boosts metabolism and inhibits fatigue. However, ERSP also concluded that the evidence submitted by the marketer was insufficient to support the claim that “Cylapril induces weight loss.” Accordingly,

 

ERSP recommended that the marketer discontinue claims that use of Cylapril will result in meaningful weight loss for consumers.

 

The company, in its advertiser’s statement said “…AFI certainly respects ERSP’s authority and views and therefore will give serious consideration to its recommendations.”

 

Subscribe to the Ad Law Insights or Privacy Initiatives newsletters for an exclusive monthly analysis and insider perspectives on the latest trends and case decisions in advertising law and data privacy.

 

 

 

 

Latest Decisions

Decision

National Advertising Division Finds Realtor.com “#1 Site Real Estate Professionals Trust” Claim Supported

New York, NY – November 8, 2024 – In a challenge brought by competitor CoStar Group, the National Advertising Division determined that Move provided a reasonable basis for its claim that Realtor.com is the “#1 site real estate professionals trust.

Read the Decision Summary
Decision

National Advertising Division Recommends Verizon Discontinue or Modify Certain Claims for Satellite-Supported Texting Services

New York, NY – November 7, 2024 – In a Fast-Track SWIFT challenge brought by T-Mobile, the National Advertising Division recommended that Verizon either discontinue certain claims about satellite-supported texting services in remote locations or modify them to disclose the necessary conditions for Verizon customers...

Read the Decision Summary
Decision

Following National Advertising Division Challenge, PetIQ Voluntarily Discontinues Certain Claims for NextStar Flea & Tick Topical

New York, NY – November 6, 2024 – Following a National Advertising Division challenge, PetIQ discontinued certain claims for its NextStar Flea & Tick topical flea prevention and treatment product, which appeared on PetIQ’s website, social media, and third-party websites.

Read the Decision Summary
Decision

National Advertising Division Finds Certain Safety Claims for Drunk Elephant Skincare Products Supported; Recommends Modification of Influencer Posts

New York, NY – November 4, 2024 – The National Advertising Division determined certain Drunk Elephant social media claims regarding skincare products being “safe for kids and tweens to use” were supported, but determined that two TikTok video influencer disclosures for Drunk Elephant's B-Goldi...

Read the Decision Summary